Current understanding of T cell immunity against SARS-CoV-2

被引:0
|
作者
Xiuyuan Lu
Sho Yamasaki
机构
[1] Osaka University,Laboratory of Molecular Immunology, Immunology Frontier Research Center
[2] Osaka University,Epitope Analysis Team, Center for Advanced Modalities and DDS
[3] Osaka University,Department of Molecular Immunology, Research Institute for Microbial Diseases
[4] Osaka University,Center for Infectious Disease Education and Research (CiDER)
[5] Kyushu University,Division of Molecular Design, Research Center for Systems Immunology, Medical Institute of Bioregulation
关键词
COVID-19; Infection; Vaccine; Adaptive immunity; Tfh; Variants; HLA; Cross-reactive T cell; HCoVs; Commensals;
D O I
暂无
中图分类号
学科分类号
摘要
As an important part of adaptive immunity, T cells are indispensable in the defense against pathogens including viruses. SARS-CoV-2 is a new human coronavirus that occurred at the end of 2019 and has caused the COVID-19 pandemic. Nevertheless, most of the infected patients recovered without any antiviral therapies, suggesting an effective immunity developed in the bodies. T cell immunity responds upon SARS-CoV-2 infection or vaccination and plays crucial roles in eliminating the viruses and generating T cell memory. Specifically, a subpopulation of CD4+ T cells could support the production of anti-SARS-CoV-2 antibodies, and cytotoxic CD8+ T cells are also protective against the infection. SARS-CoV-2–recognizing T cells could be detected in SARS-CoV-2–unexposed donors, but the role of these cross-reactive T cells is still in debate. T cell responses could be diverse across individuals, mainly due to the polymorphism of HLAs. Thus, compared to antibodies, T cell responses are generally less affected by the mutations of SARS-CoV-2 variants. Up to now, a huge number of studies on SARS-CoV-2–responsive T cells have been published. In this review, we introduced some major findings addressing the questions in the main aspects about T cell responses elicited by SARS-CoV-2, to summarize the current understanding of COVID-19.
引用
下载
收藏
相关论文
共 50 条
  • [41] Enhanced immunity against SARS-CoV-2 in returning Chinese individuals
    Yuan, Runyu
    Chen, Huimin
    Yi, Lina
    Li, Xinxin
    Hu, Ximing
    Li, Xing
    Zhang, Huan
    Zhou, Pingping
    Liang, Chumin
    Lin, Huifang
    Zeng, Lilian
    Zhuang, Xue
    Ruan, Qianqian
    Chen, Yueling
    Deng, Yingyin
    Liu, Zhe
    Lu, Jing
    Xiao, Jianpeng
    Chen, Liang
    Xiao, Xincai
    Li, Jing
    Li, Baisheng
    Li, Yan
    He, Jianfeng
    Sun, Jiufeng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [42] Innate immunity: the first line of defense against SARS-CoV-2
    Michael S. Diamond
    Thirumala-Devi Kanneganti
    Nature Immunology, 2022, 23 : 165 - 176
  • [43] Capturing adaptive immunity against SARS-CoV-2 in patients with cancer
    Hendrik Luxenburger
    Robert Thimme
    Nature Cancer, 2021, 2 : 1298 - 1300
  • [44] Cellular immunity against SARS-CoV-2 depends on the serological status
    Pighi, Laura
    Henry, Brandon M.
    De Nitto, Simone
    Salvagno, Gian Luca
    Lippi, Giuseppe
    JOURNAL OF INFECTION, 2023, 87 (01) : 57 - 58
  • [45] Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
    Achdout, Hagit
    Vitner, Einat. B.
    Politi, Boaz
    Melamed, Sharon
    Yahalom-Ronen, Yfat
    Tamir, Hadas
    Erez, Noam
    Avraham, Roy
    Weiss, Shay
    Cherry, Lilach
    Bar-Haim, Erez
    Makdasi, Efi
    Gur, David
    Aftalion, Moshe
    Chitlaru, Theodor
    Vagima, Yaron
    Paran, Nir
    Israely, Tomer
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [46] Eye drop vaccination gives immunity against SARS-CoV-2
    Schrage, Norbert
    Blomet, Joel
    Holzer, Frank
    Tromme, Adrien
    Ectors, Fabien
    Desmecht, Daniel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [47] Humoral and cellular immunity against diverse SARS-CoV-2 variants
    Chen, Changxu
    Wang, Xin
    Zhang, Zeli
    JOURNAL OF GENETICS AND GENOMICS, 2023, 50 (12) : 934 - 947
  • [48] Innate immunity: the first line of defense against SARS-CoV-2
    Diamond, Michael S.
    Kanneganti, Thirumala-Devi
    NATURE IMMUNOLOGY, 2022, 23 (02) : 165 - 176
  • [49] ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
    Henden, A.
    Lineburg, K.
    Le Texier, L.
    Raju, J.
    Crooks, P.
    Wright, E.
    Scott, A.
    Neller, M. A.
    Tey, S.
    Khanna, R.
    Smith, C.
    CYTOTHERAPY, 2023, 25 (06) : S252 - S252
  • [50] Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
    Yatim, Nader
    Boussier, Jeremy
    Tetu, Pauline
    Smith, Nikaia
    Bruel, Timothee
    Charbit, Bruno
    Barnabei, Laura
    Corneau, Aurelien
    Da Meda, Laetitia
    Allayous, Clara
    Baroudjian, Barouyr
    Jebali, Majdi
    Herms, Florian
    Grzelak, Ludivine
    Staropoli, Isabelle
    Calmettes, Vincent
    Hadjadj, Jerome
    Peyrony, Olivier
    Cassius, Charles
    LeGoff, Jerome
    Kramkimel, Nora
    Aractingi, Selim
    Fontes, Magnus
    Blanc, Catherine
    Rieux-Laucat, Frederic
    Schwartz, Olivier
    Terrier, Benjamin
    Duffy, Darragh
    Lebbe, Celeste
    SCIENCE ADVANCES, 2021, 7 (34)